Complementary Cardioprotection and Efferocytosis by Circulating Vesicle Recruitment and SIRPα Blockade after Myocardial Ischemia/Reperfusion

Acute myocardial infarction (AMI) causes heart failure and mortality, driven by ischemia/reperfusion (I/R) injury and CD47/Signal regulator protein α (SIRPα)-impaired efferocytosis that together sustain tissue damage. Endogenous plasma small extracellular vesicles (P-EVs) offer an endogenous, multifunctional option, yet their cardioprotective efficacy is limited by low cardiac accumulation. Herein, a nanosystem (SαV-DAb) was developed by functionalizing SIRPα-variant-overexpressing nanovesicles (SαV) with dual antibodies (DAb) against CD42b (platelet marker) and CD63 (EV marker) via a reactive oxygen species (ROS)-cleavable linkage. This configuration allows the nanovesicles to hitchhike on circulating platelets for targeted delivery to the ischemic heart, while simultaneously capturing and enriching protective circulating P-EVs in the lesion. SαV could bind to CD47, avoiding the SIRPα activation on macrophages and promoting efferocytosis. SαV-DAb demonstrated significantly enhanced cardiac accumulation and promoted targeted delivery of P-EVs to the ischemic myocardium. Treatment with SαV-DAb elicited a coordinated therapeutic response, including anti-apoptosis, pro-angiogenesis, and pro-efferocytosis, ultimately leading to attenuated ventricular fibrosis and improved systolic function after I/R injury, with no observable toxicity. This strategy simplifies the preparation workflow by avoiding prior isolation of PLTs and protective vesicles, and provides a conceptual framework for endogenous-system-based nanomedicine in cardiac repair.

Authors

Institutions

Publication Details

Journal
Advanced Science
Published
2026-11-16
DOI
https://doi.org/10.1002/advs.78697
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Complementary Cardioprotection and Efferocytosis by Circulating Vesicle Recruitment and SIRPα Blockade after Myocardial Ischemia/Reperfusion

Guihao Chen, Ziqin Zhou, Yuejin Yang, Qi Pan et al.
2 links
Advanced Science
Extracellular vesicles in disease
article

Complementary Cardioprotection and Efferocytosis by Circulating Vesicle Recruitment and SIRPα Blockade after Myocardial Ischemia/Reperfusion

Guihao Chen, Ziqin Zhou, Yuejin Yang, Qi Pan, Yao Jiang, Yuanwei Pan, Ye Zhu, Ling Yu
article en

Abstract

Acute myocardial infarction (AMI) causes heart failure and mortality, driven by ischemia/reperfusion (I/R) injury and CD47/Signal regulator protein α (SIRPα)-impaired efferocytosis that together sustain tissue damage. Endogenous plasma small extracellular vesicles (P-EVs) offer an endogenous, multifunctional option, yet their cardioprotective efficacy is limited by low cardiac accumulation. Herein, a nanosystem (SαV-DAb) was developed by functionalizing SIRPα-variant-overexpressing nanovesicles (SαV) with dual antibodies (DAb) against CD42b (platelet marker) and CD63 (EV marker) via a reactive oxygen species (ROS)-cleavable linkage. This configuration allows the nanovesicles to hitchhike on circulating platelets for targeted delivery to the ischemic heart, while simultaneously capturing and enriching protective circulating P-EVs in the lesion. SαV could bind to CD47, avoiding the SIRPα activation on macrophages and promoting efferocytosis. SαV-DAb demonstrated significantly enhanced cardiac accumulation and promoted targeted delivery of P-EVs to the ischemic myocardium. Treatment with SαV-DAb elicited a coordinated therapeutic response, including anti-apoptosis, pro-angiogenesis, and pro-efferocytosis, ultimately leading to attenuated ventricular fibrosis and improved systolic function after I/R injury, with no observable toxicity. This strategy simplifies the preparation workflow by avoiding prior isolation of PLTs and protective vesicles, and provides a conceptual framework for endogenous-system-based nanomedicine in cardiac repair.

Advanced Science
Nanchang University (CN), Chinese University of Hong Kong (HK), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), State Administration of Traditional Chinese Medicine of the People's Republic of China (CN), Shenzhen Bay Laboratory (CN), Guangdong Provincial Hospital of Traditional Chinese Medicine (CN), Guangdong Academy of Medical Sciences (CN), Guangdong Provincial People's Hospital (CN), Fu Wai Hospital (CN), State Key Laboratory of Cardiovascular Disease (CN), Southern Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon